StockData
Surrozen, Inc./DE logo

Surrozen, Inc./DE (SRZN) stock

SRZNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 5/30
$29.98−2.34 (-7.24%)

Close on Nov 17, 2026Market cap $352.37MP/E –Yield –

Surrozen operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Surrozen's operating cash flow for the twelve months ending Jun 30, 2026 was -$34.76M. For fiscal 2025 it was -$30.24M. The highest annual figure on record is -$17.63M in fiscal 2024.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$30.24M–
FY2024Dec 31, 2024-$17.63M–
FY2023Dec 31, 2023-$40.36M–
FY2022Dec 31, 2022-$44.15M–
FY2021Dec 31, 2021-$48.81M–
FY2020Dec 31, 2020-$29.10M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$7.42M–
Q1 FY2026Mar 31, 2026-$12.50M–
Q4 FY2025Dec 31, 2025-$5.81M-267.0%
Q3 FY2025Sep 30, 2025-$9.04M–
Q2 FY2025Jun 30, 2025-$6.11M–
Q1 FY2025Mar 31, 2025-$9.28M–
Q4 FY2024Dec 31, 2024$3.48M–
Q3 FY2024Sep 30, 2024-$6.75M–
Q4 FY2023Dec 31, 2023-$7.31M–
Q3 FY2023Sep 30, 2023-$10.13M–
Q2 FY2023Jun 30, 2023-$8.75M–
Q1 FY2023Mar 31, 2023-$14.17M–
Q4 FY2022Dec 31, 2022-$205.00K–
Q3 FY2022Sep 30, 2022-$14.15M–
Q2 FY2022Jun 30, 2022-$11.41M–
Q1 FY2022Mar 31, 2022-$18.37M–
Q4 FY2021Dec 31, 2021-$11.54M–
Q3 FY2021Sep 30, 2021-$14.06M–
Q2 FY2021Jun 30, 2021-$12.88M–
Q1 FY2021Mar 31, 2021-$10.33M–
Q4 FY2020Dec 31, 2020-$9.34M–

More Surrozen figures

See a number that looks wrong?